Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | EGFR |
Clinical data | |
Trade names | Portrazza |
AHFS/Drugs.com | Multum Consumer Information |
Routes of administration |
Intravenous infusion |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Biological half-life | ~14 days |
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6436H9958N1702O2020S42 |
Molar mass | 144.84 kg/mol |
(what is this?) |
Necitumumab (INN) is a recombinant human IgG1 monoclonal antibody used as an antineoplastic. It binds to the epidermal growth factor receptor (EGFR). The US FDA approved necitumumab under the brand name Portrazza for use with gemcitabine and cisplatin in previously untreated metastatic squamous non-small-cell lung carcinoma (NSCLC). It was counterproductive in non-squamous non-small-cell lung carcinoma.